[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100079533":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":16,"responsibleParty":7,"collaborators":7,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":7,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":7,"enrollmentInfo":38,"targetDuration":7,"studyType":40,"phases":7,"briefSummary":41,"conditions":42,"keywords":44,"overallStatus":50,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":61},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","celecoxib 400 mg BID",[13],{"name":14,"affiliation":5,"role":15},"Carol J Fabian, MD","PRINCIPAL_INVESTIGATOR",[17],{"facility":5,"status":7,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"Kansas City","Kansas","66160","United States","US",{"type":24,"coordinates":25},"Point",[26,27],-94.62746,39.11417,{"lat":27,"lon":26},"100079533","an-examination-of-predictors-of-indicators-of-response-to-celecoxib-in-women-who-have-a-diagnosis-of-early-breast-cancer-100079533",false,"NCT00291122","An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer","Quantitative Real Time PCR in Formalin Fixed Breast Tissue From Biopsy and Re-Excision Specimens: An Ancillary Protocol to a Chemoprevention Trial of Celecoxib","Inclusion Criteria:\n\n* women with a recent diagnosis of T1 or T2 noninvasive breast cancer by large core needle or excisional biopsy\n* confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post diagnostic analyses to perform research assessments\n* reexcision planned within 10 days to 6 weeks from study start\n\nExclusion Criteria:\n\n* no hormone replacement therapy within 90 days prior to biopsy\n* no history of asthma, allergy ASA, NSAIDS, celecoxib of other COX-2 inhibitors for a chronic non-oncological condition with the excision of low dose ASA (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study\n* no celecoxib or rofecoxib use within one month of biopsy\n* no history of gastrointestinal ulcer or ulcerative colitis requiring treatment\n* no current anticoagulants\n* no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study\n* no aromatase inhibitor in the six months prior to participation\n* no concomitant lithium\n* no known significant bleeding disorder","FEMALE","18 Years",{"count":39,"type":7},100,"OBSERVATIONAL","To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.",[43],"Breast Cancer",[45,46,47,48,49],"breast atypia","breast epithelial hyperplasia","ki-67","RTPCR","microdissection","COMPLETED","2008-09-15",{"date":53,"type":54},"2008-09-16","ESTIMATED",{"date":56,"type":7},"2003-01",{"date":58,"type":7},"2005-12",{"name":60,"class":6},"University of Kansas",1]